Trial reportThe European respiratory journal2022
Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial.
Trial report in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Tuberculosis preventive treatment among individuals with inactive tuberculosis suggested by untreated radiographic abnormalities: a community-based randomized controlled trial.Emerging microbes & infections · 2023Trial
- The latent tuberculosis infection survey using two interferon γ release assay tests among the elderly in a well-confined rural county in Eastern China.BMC geriatrics · 2025Article
- Prognostic value of an abnormal chest X-ray result in predicting the development of tuberculosis.Nature communications · 2025Article
- Impact of detection rate and preventive treatment of latent tuberculosis infection on the future burden of tuberculosis among students in shanghai: a predictive study using Markov modeling.BMC public health · 2025Article
- The dynamic change of tuberculosis infection prevalence in rural residents: 10-year follow-up of a population-based, multicentre cohort study from China.The Lancet regional health. Western Pacific · 2025Article
- Clinical and Mycobacterium tuberculosis strain characteristics of tuberculosis patients with diabetes mellitus in Changping District, Beijing, China.BMC infectious diseases · 2025Article
- Cost-effectiveness analysis of tuberculosis screening in diabetic patients in China: a decision-analytic Markov model.Frontiers in public health · 2025Article
- Performance comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in detectingPeerJ · 2025Article
- Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Tuberculosis screening characteristics amongst freshmen in Changping District, Beijing, China.BMC infectious diseases · 2023Article
- Long-term economic evaluation of the recombinantFrontiers in pharmacology · 2023Article
- Recombinant mycobacterium tuberculosis fusion protein for diagnosis of mycobacterium tuberculosis infection: a short-term economic evaluation.Frontiers in public health · 2023Article
- Relationship between DNA Methylation Profiles and Active Tuberculosis Development from Latent Infection: a Pilot Study in Nested Case-Control Design.Microbiology spectrum · 2022Article
- Serial testing of latent tuberculosis infection in patients with diabetes mellitus using interferon-gamma release assay, tuberculin skin test, and creation tuberculin skin test.Frontiers in public health · 2022Article
- Whole transcriptome sequencing reveals neutrophils' transcriptional landscape associated with active tuberculosis.Frontiers in immunology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnlarging tuberculosis (TB) preventive treatment among at-risk populations is a critical component of the End TB Strategy. There is an urgent need to develop suitable latent tuberculosis infection (LTBI) testing and treatment tools according to the local TB epidemic and available resources worldwide.
methodsBased on an open-label randomised controlled trial conducted since 2015 in China among rural residents aged 50-70 years with LTBI, the protective efficacy of a 6-week twice-weekly regimen of rifapentine plus isoniazid was further evaluated in a 5-year follow-up survey.
results1298 treated participants and 1151 untreated controls were included in the 5-year protective efficacy analysis. In the per-protocol analysis, the incidence rate was 0.49 (95% CI 0.30-0.67) per 100 person-years in the untreated control group and 0.19 (95% CI 0.07-0.32) per 100 person-years in the treated group; the protection rate was 61.22%. Subgroup analysis showed that the protection rate was 76.82% in the per-protocol analysis among participants with baseline interferon (IFN)-γ levels in the highest quartile (≥3.25 IU·mL
conclusionsOur findings suggest the 6-week twice-weekly regimen of rifapentine plus isoniazid for LTBI treatment might be an optional tool for TB control in the Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.